Judge Grants Final Approval of $345 Million Settlement with the Pfizer Defendants in EpiPen Class Action

November 17, 2021 – Today, Judge Daniel D. Crabtree granted final approval of the settlement between Plaintiffs and the Pfizer Defendants in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, proceeding in the United States District Court for the District of Kansas. Pritzker Levine partner Elizabeth C. Pritzker serves as Co-Lead Class Counsel in the case.

Plaintiffs allege that the Pfizer and Mylan Defendants engaged in anticompetitive behavior that resulted in huge increases in the price of auto-injectable EpiPen devices, which are used to treat life-threatening allergic reactions. The settlement resolves Plaintiffs’ claims against the Pfizer Defendants, and will result in compensation for consumers who purchased a name brand or authorized generic EpiPen device between August 24, 2011, and November 1, 2020 and submitted a timely claim, as well as for third-party payors.

In his order, Judge Crabtree granted service awards to Class Representatives commensurate with the hours they dedicated to the case and also awarded Class Counsel their requested attorneys’ fees and expenses, recognizing “the skill and zeal” brought to the case by Co-Lead Counsel, as well as the “exceptional legal work” that they performed on behalf of their clients and the Class.

Plaintiffs’ remaining claims against the Mylan Defendants and former Mylan CEO Heather Bresch are scheduled to go to trial. The trial will commence on January 24, 2022, in Kansas City, KS.

About Pritzker Levine

Pritzker Levine LLP is national litigation firm with offices in California and New York. The firm serves corporate clients, public entities, pension funds, small businesses, nonprofit groups, labor unions, whistleblowers and injured persons in cases involving antitrust violations, securities fraud and derivative claims, commercial disputes, consumer protection, financial wrongdoing, employment law and personal injuries.